EOS imaging Gains CE Mark for hipEOS, the First 3D Stereoradiographic Planning Software

Regulatory News:

EOS Imaging (Paris:EOSI) (NYSE Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, announced today the CE mark of hipEOS, a 3D hip arthroplasty planning software based on EOS biplanar 3D imaging.

hipEOS is the first of a software portfolio offering to be associated with an EOS imaging system. It is based on EOS low dose 3D images and technology from OneFit Medical, a company EOS imaging acquired in late 2013. It will initially be deployed as an on line service to allow surgeons in hip prosthesis selection and placement simulation based upon 3D images generated by the EOS system.

Prof. Didier Mainard (Nancy University Hospital, France) said, "hipEOS enables physicians and surgeons to select the best fit prosthesis for each patient using 2D and 3D images and the EOS imaging data set. The 3D element of the software takes away a lot of the guesswork out of prosthesis sizing and should allow surgeons to perform these replacements more efficiently thanks to a better anticipation.”

Marie Meynadier, CEO of EOS imaging, said, "The acquisition of OneFit and subsequent development of surgical planning software such as hipEOS allow us to associate to our unique imaging platform offerings with strong value for the surgical care pathways. The EOS system, with its 2D/3D capabilities, redefines a class for musculoskeletal imaging, and the addition of complementary software will further strengthen and extend this core offering. hipEOS is the first step towards the development of a comprehensive offering of dedicated, surgeon centric software and hardware tools based from EOS unique technology”.

EOS imaging will exhibit at AAOS 2014, March 11-15 at the Morial Convention Center, Booth #2335.

For more information, please visit www.eos-imaging.com.

About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 80 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 102 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: 2013 annual results on April 8, 2014 (after market).